MAGEA3 and head and neck squamous cell carcinoma: A pilot study with Trojan vaccines, composed of HLA-I- and HLA-II-restricted MAGE-A3 or HPV-16 derived peptides, joined by furin-cleavable linkers and linked to a penetrin peptide sequence, showed the vaccine to have acceptable toxicity and good systemic immune responses against the HLA-II-restricted epitopes in five MAGE -A3/HPV 16+ patients of R/M HNSCC [106].